Skip to content

Clinical course of hepatic abnormalities in overweight and obese children

Clinical course of hepatic abnormalities in overweight and obese children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20210322008
Enrollment
74
Registered
2021-03-22
Start date
2019-10-29
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight Obesity Non-alcoholic fatty liver disease Overweight Obesity Non-alcoholic fatty liver disease

Interventions

All pediatric patient with obese and overweight who are enrolled into the study. Overweight children are those with body mass index Z-score more than 1 standard deviation of their age. Obese children
Diagnostic
Obese and overweight pediatric patients

Sponsors

Chulalongkorn university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Children aged 5-18 years 2.Diagnosed overweight or obese 3.Follow up at Chulalongkorn hospital at lease 6 months

Exclusion criteria

Exclusion criteria: 1.Fatty liver disease with known causes such as Wilson disease, drugs, or autoimmune hepatitis 2.Obesity from syndromes 3.Loss second follow-up

Design outcomes

Primary

MeasureTime frame
Progression of NAFLD At first visit and second visit which was at least 6 months apart CAP, AST, ALT

Secondary

MeasureTime frame
NAFLD progression between patients with and without comorbidity At first visit and second visit which was at least 6 months apart CAP, AST, ALT,NAFLD progression between patients attending multi-specialty clinic and single specialty clinic At first visit and second visit which was at least 6 months apart CAP, AST, ALT

Countries

Thailand

Contacts

Public ContactRatikorn Prugmahachaikul

Chulalongkorn University

ratikornprug@gmail.com0870099960

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026